From the Editor

From the Desk of the Editor: "Targeting the Unseen: Advances in Treatment of M0 CRPC"

Alicia Morgans
April 13, 2018

Biochemical or PSA-only recurrence of prostate cancer after initial treatment with surgery or radiation can be extremely stressful for patients and their families, particularly when the PSA rises quickly. In the last few weeks the field has been fortunate to hear reports of two practice changing studies for men with high-risk non-metastatic castration-resistant prostate cancer (M0CRPC) that make some strides in combating this issue. The Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide

READ MORE PREVIOUS ARTICLES

Alicia Morgans, MD

Alicia Morgans, MD, MPH

Alicia Morgans, MD, MPH is an Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. She completed her MD and internal medicine residency at the University Of Pennsylvania Perelman School Of Medicine, and her fellowship at Dana Farber Cancer Institute/MGH Cancer Center. She is a clinician and physician investigator specializing is investigating complications of systemic therapy for prostate cancer survivors. Her work has included the study of skeletal, cardiovascular, diabetic, and cognitive complications of prostate cancer survivorship, as well as treatment decision making in the metastatic prostate cancer population. She has expertise in clinical trials and patient reported outcome measures, and as well as incorporating patient preferences and beliefs into clinical decision making.

Video Lectures
State-of-the-industry video lectures by leading urology experts
Conference Highlights
Recent data from conferences worldwide

AUA 2018 Prostate Cancer

ASCO GU 2018 Prostate Cancer

ESOU18 Prostate Cancer

SUO 2017 - Prostate Cancer

SIU 2017 Prostate Cancer

ESMO 2017 Prostate Cancer

CUA 2017

ASCO 2017 Prostate Cancer

AUA 2017 Prostate Cancer

EAU 2016 - Prostate Cancer